Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults TS ID 10515Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC